cd38 inhibitor and 5-amino-1mq synergy nad+ CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents Frontiers | Nicotinamide N-methyltransferase (NNMT):
Frontiers Nicotinamide N methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome Targeting NAD+ Synthesis to Potentiate CD38 Based Immunotherapy of Multiple Myeloma ScienceDirect The Pharmacology of CD38 NADase: An emerging target for cancer and aging diseases PMC CD38 is a key mediator of NAD+ depletion in the brain of ZIKV infected mice: iScience Inhibition of CD38 enzymatic activity enhances CAR T cell immune therapeutic efficacy by repressing glycolytic metabolism ScienceDirect
Pay in 4 interest-free payments of $6.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 13 - Sep 18




